Abstract
The present study examined the opioid receptors involved in the antitussive effect of dihydroetorphine in mice. Dihydroetorphine suppressed coughs dose dependently at doses between 0.1-1 micrograms/kg i.p. Blockade of mu-opioid receptors by pretreatment with beta-funaltrexamine significantly reduced the antitussive effect of dihydroetorphine. Furthermore, the antitussive effect of dihydroetorphine was also antagonized by nor-binaltorphimine, a kappa-opioid receptor antagonist. However, pretreatment with naltrindole, a delta-opioid receptor antagonist, did not affect the antitussive effect of dihydroetorphine. These results indicate that the antitussive effect of dihydroetorphine is mediated by the activation of mu-opioid receptors and of kappa-opioid receptors, but not delta-opioid receptors.
MeSH terms
-
Alkylating Agents / pharmacology
-
Animals
-
Antitussive Agents / administration & dosage
-
Antitussive Agents / pharmacology*
-
Antitussive Agents / therapeutic use
-
Cough / drug therapy*
-
Dose-Response Relationship, Drug
-
Etorphine / administration & dosage
-
Etorphine / analogs & derivatives*
-
Etorphine / pharmacology
-
Etorphine / therapeutic use
-
Injections, Intraperitoneal
-
Male
-
Mice
-
Naltrexone / analogs & derivatives
-
Naltrexone / pharmacology
-
Narcotic Antagonists / pharmacology
-
Receptors, Opioid / drug effects*
-
Receptors, Opioid / metabolism
-
Receptors, Opioid, delta / drug effects
-
Receptors, Opioid, delta / metabolism
-
Receptors, Opioid, kappa / drug effects
-
Receptors, Opioid, kappa / metabolism
-
Receptors, Opioid, mu / drug effects
-
Receptors, Opioid, mu / metabolism
Substances
-
Alkylating Agents
-
Antitussive Agents
-
Narcotic Antagonists
-
Receptors, Opioid
-
Receptors, Opioid, delta
-
Receptors, Opioid, kappa
-
Receptors, Opioid, mu
-
binaltorphimine
-
Etorphine
-
Naltrexone
-
beta-funaltrexamine
-
18,19-dihydroetorphine